

Cambridge University Press

978-1-107-03922-3 - Neuropsychiatric and Cognitive Changes in Parkinson's Disease and Related Movement Disorders: Diagnosis and Management

Edited by Dag Aarsland, Jeffrey Cummings, Daniel Weintraub and K. Ray Chaudhuri

Index

[More information](#)

# Index

- acetylcholine  
   cholinergic dysfunction, 26  
     as risk factor for psychosis, 156  
   functional imaging, 92  
 acetylcholinesterase (AChE) activity,  
   92, *see also* cholinesterase  
   inhibitors  
 aggression, deep brain stimulation  
   (DBS) effect, 235  
 agitation management, 288  
 agoraphobia, 67–8, 122  
 alpha-synuclein (SNCA), 2, 15, 97  
   as biomarker, 100–2  
   diagnostic significance, 43  
   elevated expression, 2  
   immunohistochemistry, 15  
   in Parkinson's disease dementia  
     (PDD), 182  
 alpha-synuclein (SNCA) gene, 2, 29,  
   179  
   duplications, 3, 14, 26, 182  
 Alzheimer's disease (AD), 17, 80,  
   *see also* dementia  
   biomarkers of cognitive decline, 97  
   tau protein, 100  
 amantadine, 9, 187, 221, 279  
 amyloid. *See* beta-amyloid  
 anger, deep brain stimulation (DBS)  
   effect, 235  
 anterior cingulate syndrome, 135  
 anticholinergics, 9  
 antidepressant therapy, 18, 112–13,  
   187, 219, *see also* depression  
   developments, 287–8  
   with psychosis, 158  
 antioxidants, 11  
 antipsychotic therapy, 157–9,  
   *see also* Parkinson's disease  
   psychosis; psychosis  
   clinical trials, 245  
   developments, 286–7  
   impulse control disorders (ICD),  
     145  
   punding, 147  
 anxiety, 18, 65, 67–8, 119, 220  
   assessment, 68–9, 124–5  
   clinical correlates, 123–4  
   clinical features, 121  
   comorbidities, 120  
   deep brain stimulation effects,  
     234–5  
   diagnostic criteria, 68  
   fluctuations, 277  
   impact, 121  
   management, 125–6, 220  
     developments, 288  
   multiple systems atrophy patients,  
     263  
   neuroimaging correlates, 79  
     functional imaging, 91  
   prevalence in PD, 67–8, 119–20, 122  
   quality of life impact, 256  
   rating scales, 68, 124–5  
   subtypes, 121–3  
 apathy, 18–19, 65, 69, 131–5  
   clinical assessment, 70  
   cognitive function relationship,  
     131–2  
   deep brain stimulation effects,  
     133–5, 234  
   depression relationship, 133  
   diagnostic criteria, 69, 131  
   fluctuations, 277  
   management, 136–7, 219  
     developments, 288  
   neuroimaging correlates, 77–8,  
     135–6  
   pathophysiology, 135–6  
   progressive supranuclear palsy  
     patients, 265–6  
   quality of life impact, 256  
   rating scales, 69–70  
 Apathy Scale (AS), 69  
 apolipoprotein E (APOE) gene, 30–1,  
   46, 178  
 apomorphine, 8, 279  
 atomoxetine, 113, 136, 172  
 attention  
   atypical parkinsonian disorders,  
     comparisons, 270  
   fluctuations in, 44  
   impairment, 179  
 atypical parkinsonian disorders, 6, 261,  
   *see also* corticobasal  
   degeneration (CBD);  
   multiple systems atrophy  
   (MSA); progressive  
   supranuclear palsy (SPS)  
   comparison, 268–71  
     attention, 270  
     cognition, 269  
     executive function, 270  
     general cognition, 268–70  
     memory, 271  
     neuropsychiatric/behavioral  
       features, 271–2  
     verbal fluency, 270  
     visuospatial skills, 270–1  
 auditory hallucinations, 154  
 autonomic dysfunction, 45, 181  
 autophagy–lysosome pathway  
   (ALP), 2  
 basal ganglia, 230–1  
 Beck Anxiety Inventory (BAI), 68  
 Beck Depression Inventory (BDI),  
   66, 109  
 benztropine, 9  
 beta-amyloid, 99, 101, 178  
   beta-amyloid 1–40 biomarker, 99  
   beta-amyloid 1–42 biomarker, 99  
   in Parkinson's disease dementia  
     (PDD), 182  
 binge eating, 77, 140, *see also* impulse  
   control disorders (ICD)  
   deep brain stimulation (DBS) effect,  
     237  
 biomarkers, 74, 98  
   Alzheimer's disease, 97  
   cerebrospinal fluid, 98–9, 101  
     alpha-synuclein, 100–2  
     beta-amyloid 1–40, 99  
     beta-amyloid 1–42, 99  
     DJ-1, 102  
     fatty acid-binding proteins  
       (FABPs), 103  
     growth-associated protein 43  
       (GAP-43), 103  
     neurofilaments, 102–3  
     tau protein, 99–100  
   developments, 289  
   for clinical trials, 250–1  
 bradykinesia, 4  
 brain  
   atrophy, 46, 83, 183  
   glucose metabolism, 89–90  
   butyrylcholinesterase (BChE) gene, 31–2

Cambridge University Press

978-1-107-03922-3 - Neuropsychiatric and Cognitive Changes in Parkinson's Disease and Related Movement Disorders: Diagnosis and Management

Edited by Dag Aarsland, Jeffrey Cummings, Daniel Weintraub and K. Ray Chaudhuri

Index

[More information](#)

## Index

- Cambridge Cognitive Assessment (CAMCOG), 59
- carbidopa, 7
- catechol-*O*-methyltransferase (COMT), 27
- genetic polymorphism, 27–9
- cognition and, 171
- inhibitors, 8
- CEP-1347, 10
- cerebral metabolic rate of glucose (rCMRglc), 89–90
- cerebrospinal fluid (CSF), 98–9
- biomarkers, 98–9, 101
- alpha-synuclein, 100–2
- beta-amyloid, 99
- DJ-1, 102
- fatty acid-binding proteins (FABPs), 103
- growth-associated protein 43 (GAP-43), 103
- neurofilaments, 102–3
- tau protein, 99–100
- chaperone-mediated autophagy (CMA), 2
- cholecystokinin (CCK) gene, 32
- cholinergic dysfunction, 26
- as risk factor for psychosis, 156
- functional imaging, 92
- cholinesterase inhibitors, 185–7
- cognitive impairment management, 26, 172
- hallucination management, 156
- Clinical Dementia Rating (CDR) scale, 57–8
- clinical trial designs, 288–9, *see also* Parkinson's disease psychosis
- parallel sequential comparison design (PSCD), 289
- withdrawal designs, 288
- clonazepam, sleep disorder management, 204
- clozapine, 19, 157–8, 219
- clinical trials, 245
- side effects, 157
- cognitive assessment, 55–60, *see also* cognitive impairment (CI)
- deep brain stimulation and, 60
- interpretation of test results, 60
- what to assess, 55
- cognitive fluctuations, 278
- cognitive impairment
- tools, 55–9
- cognitive impairment (CI), 16–17, 53–5, 212
- apathy relationship, 131–2
- assessment, 56, 185, *see also specific instruments*
- deep brain stimulation and, 60
- interpretation of test results, 60
- level 1 tests, 56–8
- level 2 tests, 58–9
- recommended scales, 61
- atypical parkinsonian disorders, comparisons, 269
- biomarkers in Alzheimer's disease, 97
- corticobasal degeneration patients, 266–70
- dementia with Lewy bodies (DLB), 45
- early changes, 163
- changes possibly preceding PD, 165–6
- prevalence, 163–5
- progression, 168–9
- fluctuations, 278
- genetic basis, 26–32, 171–2, 179
- heterogeneity, 212
- impulse control disorder (ICD)
- relationship, 142–3
- mechanisms, 170
- mild. *See* mild cognitive impairment (MCI)
- multiple system atrophy patients, 261–3, 268–70
- neuroimaging correlates, 79–81
- functional imaging, 170–1
- Parkinson's disease dementia (PDD), 45
- progressive supranuclear palsy patients, 264–5, 268–70
- quality of life impact, 257–8
- risk factors, 178
- treatment, 172
- white matter changes and, 84
- cognitive-behavioral therapy (CBT)
- anxiety, 126–7
- depression, 114
- compulsive gambling, 77, 140, 145, *see also* impulse control disorders (ICD)
- deep brain stimulation (DBS) effect, 237
- diagnostic criteria, 141
- compulsive sexual behavior, 140, *see also* impulse control disorders (ICD)
- deep brain stimulation (DBS) effect, 237
- COMT. *See* catechol-*O*-methyltransferase
- COMT inhibitors, 8
- constipation, 5
- management, 10
- Cornell Scale for Depression in Dementia (CSDD), 66
- cortical atrophy, 46
- corticobasal degeneration (CBD), 266–8
- cognitive features, 266–7
- comparative studies, 268–72
- attention, 270
- general cognition, 268–70
- memory, 271
- verbal fluency, 270
- visuospatial skills, 270–1
- neuropsychiatric/behavioral features, 267–8
- DAT. *See* dopamine transporter
- DDS. *See* dopamine dysregulation syndrome
- decision making, dopaminergic treatment impacts, 217–18
- deep brain stimulation (DBS), 9–10
- cognitive assessment
- importance, 60
- fluctuating symptom management, 280
- impulse control disorder
- relationship, 221
- neuropsychiatric symptoms and, 230–2, 280
- anger, 235
- anxiety, 234–5
- apathy, 133–5, 234
- behavioral symptoms, 235–6
- depression, 113–14, 233–4
- impulse control disorder, 145
- impulse control disorder (ICD), 236–8
- mania, 232–3
- psychosis, 239
- punding, 238
- social adjustment, 238
- suicidal behavior, 235, 238–9
- psychosis and, 159
- sleep disorder management, 205
- delusions, 154, 180, *see also* psychosis
- treatment, 157
- dementia, 17, 81, *see also* dementia with Lewy bodies (DLB); Parkinson's disease dementia (PDD)
- definition, 41
- genetic basis, 26–32, 178–9
- APOE gene, 30–1, 178
- BCHE gene, 31–2
- GBA gene, 32, 179
- MAPT gene, 29–30, 179
- neurocognitive predictors, 169–70
- neuroimaging correlates, 81–3
- risk factors, 177–8
- Dementia Rating Scale (DRS), 58

Cambridge University Press

978-1-107-03922-3 - Neuropsychiatric and Cognitive Changes in Parkinson's Disease and Related Movement Disorders: Diagnosis and Management

Edited by Dag Aarsland, Jeffrey Cummings, Daniel Weintraub and K. Ray Chaudhuri

Index

[More information](#)

## Index

- dementia with Lewy bodies (DLB), 20, 30
- biomarkers, 99–100
- boundaries with Parkinson's disease dementia (PDD), 40, 47–8
- clinical criteria, 40–2
- clinical symptoms, 44–6
- neurochemistry, 43–4
- neuropathology, 42–3
- definition, 41
- diagnosis, 46–7
- cognitive tests, 46–7
- diagnostic criteria, 155
- functional imaging, 46–7, 90, 92–3
- structural imaging, 46
- transcranial sonography, 47
- heredity, 46
- symptoms, 44–6
- autonomic dysfunction, 45
- cognitive impairment, 45
- dysphagia, 46
- fluctuations in attention and wakefulness, 44
- hallucinations, 75, 154–5
- neuroleptic hypersensitivity, 46
- parkinsonism, 44
- sleep disturbance, 45
- treatment, 47
- depression, 17–18, 65, 109
- apathy relationship, 133
- as prodromal syndrome of PD, 110
- clinical assessment, 67
- comorbidities, 120
- consequences of in PD, 112
- corticobasal degeneration patients, 267
- course of, 110
- deep brain stimulation effects, 113–14, 233–4
- diagnosis, 109
- diagnostic criteria, 65–6
- fluctuations, 277
- genetic basis, 33
- levodopa effects, 112
- management, 112–14, 204–5, 219–20
- antidepressants, 112–13, 187, 219, 287–8
- antiparkinsonian treatments, 113–14
- electroconvulsive therapy, 114
- emerging antidepressant agents, 287–8
- psychotherapy, 114
- mechanisms, 110–12
- frontal-subcortical circuits, 111
- genetic factors, 111
- neurotransmitter changes, 111–12
- psychosocial factors, 112
- structural brain changes, 111
- multiple system atrophy patients, 263
- neuroimaging correlates, 78–9, 111
- functional imaging, 91
- prevalence in PD, 65, 109–10
- prognostic significance, 65
- progressive supranuclear palsy patients, 266
- quality of life impact, 256
- rating scales, 66–7, 109
- risk factors, 110
- screening, 66–7
- sleep disorder relationship, 204–5
- subsyndromal, 277
- symptoms, 109
- desipramine, 113
- dextromethorphan-quinidine combination (DM/Q), 288
- disease-modifying treatments, 250–1, 285–6
- disinhibition, progressive supranuclear palsy patients, 266
- DLB. *See* dementia with Lewy bodies (DLB)
- donepezil, 47, 158, 186
- dopamine (DA)
- asymmetric striatal depletion, 215
- fluctuating release, 215
- functional imaging, 90–1
- dopaminergic receptors, 91
- presynaptic function, 90–1
- genetic regulation, 27–9
- psychosis relationship, 157
- dopamine agonists (DA), 8–9, *see also* dopaminergic treatment
- apathy management, 137
- fluctuating symptom management, 279
- impulse control disorder (ICD) relationship, 140–2
- management issues, 145
- dopamine dysregulation syndrome (DDS), 147–8, 221, 277
- assessment, 148
- clinical features, 147
- deep brain stimulation (DBS) effect, 237–8
- diagnostic criteria, 147
- etiology, 147
- management, 148
- prevalence, 147
- Dopamine Dysregulation Syndrome-Patient and Caregiver Inventory (DDS-PC), 145
- dopamine membrane transporter (DAT), 27, 90
- DAT gene, 32
- DAT scan, 6
- early cognitive impairment and, 166
- impulse control disorder and, 143
- dopaminergic cell loss, 3, 43
- dopaminergic treatment. *See also* dopamine agonists (DA); levodopa
- behavioral impacts, 211
- motivation and decision making, 217–18
- cognitive impacts, 211
- genetic influence, 215
- individual variations, 215–17
- level of dopaminergic depletion association, 213–15
- rationale, 212–13
- depression relationship, 112–13
- fluctuating response, 215, *see also* motor fluctuations; non-motor fluctuations
- side effects, 8–9
- hallucinations, 32, 218
- impulse control disorder (ICD), 19, 33, 77, 140–1
- psychosis, 32
- punding, 146
- dorsal striatum, 214
- drooling, 10
- drug-induced parkinsonism, 6
- dysautonomia, 5–6
- dyskinesia, 7, 276
- dysphagia, 10, 46
- electroconvulsive therapy (ECT)
- depression, 114
- with psychosis, 158
- entacapone, 8
- environmental exposures, 1
- erectile dysfunction, 6, 10
- excessive daytime sleepiness (EDS), 181, 197–8
- causes, 198
- driving and, 198
- management, 188, 204
- executive dysfunction, 26, 179–80
- atypical parkinsonian disorders, comparisons, 270
- fatigue, quality of life impact, 256–7
- fatty acid-binding proteins (FABPs), 103
- Fazekas' scale, 75
- fibrillar amyloid, 92–3
- fluctuations in medication response. *See* motor fluctuations; non-motor fluctuations (NMFs)
- fractional anisotropy (FA), 74, 183
- Frontal Assessment Battery (FAB), 58

Cambridge University Press

978-1-107-03922-3 - Neuropsychiatric and Cognitive Changes in Parkinson's Disease and Related Movement Disorders: Diagnosis and Management

Edited by Dag Aarsland, Jeffrey Cummings, Daniel Weintraub and K. Ray Chaudhuri

Index

[More information](#)

## Index

- functional imaging, 46–7, 89, *see also* neuroimaging studies
- changes in functional activity, 89–90
- fibrillar amyloid, 92–3
- neuroinflammation, 93–4
- neurotransmitter activity, 90–2
  - cholinergic function, 92
  - dopaminergic function, 90–1
  - noradrenergic function, 91–2
  - serotonergic function, 91
- functional magnetic resonance imaging (fMRI). *See* functional imaging; magnetic resonance imaging (MRI)
- galantamine, 158, 186
- gambling, pathological, 77, 140, 145, *see also* impulse control disorders (ICD)
  - deep brain stimulation (DBS) effect, 237
  - diagnostic criteria, 141
- Gaucher's disease, 32
- gene therapy, 11
- generalized anxiety disorder (GAD), 67, 69, 121–3
- genetics, 1–3, 25
  - autosomal dominant forms of PD, 3
  - autosomal recessive form of PD, 3
  - dopaminergic treatment interaction, 215
  - impulse control disorders (ICD), 143
  - non-motor symptoms, 25–6, 34–5
    - cognitive impairment, 26–32, 171–2, 179
    - dementia, 26–32, 178–9
    - depression, 33
    - hallucinations, 32–3
    - impulse control disorders, 33–4
    - psychosis, 32–3
- Geriatric Depression Scale (GDS), 66, 109
- glucocerebrosidase (*GBA*) gene, 32, 172, 179
- glucose metabolism, brain, 89–90
- growth-associated protein 43 (*GAP-43*), 103
- hallucinations, 19–20, 153–5, 218
  - deep brain stimulation effects, 239
  - dementia with Lewy bodies (DLB), 75
  - dopaminergic treatment relationships, 218
  - fluctuations, 277–8
  - genetic basis, 32–3
  - management, 157, 187
  - neuroimaging correlates, 78–80
  - Parkinson's disease dementia (PDD), 75, 180
  - prevalence, 153
  - recurrence, 159
  - work up, 219
- Hamilton Anxiety Rating Scale (HAM-A), 68, 124
- Hamilton Depression Rating Scale (HAM-D), 66, 109
- health-related quality of life (HRQoL), 255–6
  - neuropsychiatric symptom impacts, 256–8
    - anxiety, 256
    - apathy, 256
    - cognitive impairment, 257–8
    - depression, 256
    - fatigue, 256–7
    - psychotic symptoms, 257
- heart-type fatty acid-binding protein (HFABP), 103
- hoarding, excessive, 146
- hobbyism, 146
- Hospital Anxiety and Depression Scale (HADS), 66, 68, 109, 124
- hypersexuality. *See* compulsive sexual behavior
- hypocretin, 195, 197
- impulse control disorders (ICD), 19, 33, 140
  - assessment, 144–5
  - cognitive performance in, 142–3
  - correlates, 141–2
  - deep brain stimulation effects, 236–8
  - diagnostic criteria, 145
  - genetic basis, 33–4, 143
  - management, 145, 220–1
    - developments, 288
  - neuroimaging correlates, 77, 143–4
  - prevalence in PD, 140–1
- inflammation, 2
  - functional imaging, 93–4
- language functions, 180
- learning, dopaminergic treatment impacts, 217–18
- leucine-rich repeat kinase 2 (*LRRK2*) mutation, 172
- levodopa, 7–8, 47, 213, *see also* dopaminergic treatment
  - cognitive effects, 214
  - individual differences, 215
  - depression relationship, 112
  - enteric administration, 279
  - fluctuations, 215, 275, *see also* motor fluctuations; non-motor fluctuations (NMFs)
  - hallucination association, 218
  - pharmacokinetic profile significance, 216–17
- Lewy bodies, 3, *see also* dementia with Lewy bodies (DLB); Lewy body disease (LBD)
  - anatomic progression, 170
  - history, 15
  - molecular biology, 14–15
- Lewy body disease (LBD), 15, 40, *see also* dementia with Lewy bodies (DLB)
  - dementia relationship, 17
  - sleep disorder relationship, 20–1
  - staging, 15–16
- Lewy neurites, 15
  - anatomic progression, 170
- Lewy, Fritz Heinrich, 14
- Lille apathy rating scale (LARS), 69
- lumbar puncture (LP), 99
- magnetic resonance imaging (MRI), 73–4, *see also* neuroimaging studies
  - 3D MRI, 73, 75
  - diffusion tensor imaging (DTI), 74
  - diffusion weighted imaging (DWI), 74
  - functional MRI, 89
- mania, deep brain stimulation effects, 232–3
- MAO-B inhibitors, 9
- MAPT* gene, 29
  - dementia relationship, 29–30, 179
  - hallucination association, 33
- Mattis Dementia Rating Scale (DRS), 58
- mean diffusivity (MD), 74
- melatonin, sleep disorder management, 204
- melperone, 158
- memantine, 47, 158, 187
- memory impairment, 166, 180
  - corticobasal degeneration patients, 267, 271
  - multiple system atrophy patients, 263, 271
  - progressive supranuclear palsy patients, 264–5, 271
- methylphenidate, 136
- mild cognitive impairment (MCI), 42, 54, 80–1, 166–8, 211, *see also* cognitive impairment (CI)

Cambridge University Press

978-1-107-03922-3 - Neuropsychiatric and Cognitive Changes in Parkinson's Disease and Related Movement Disorders: Diagnosis and Management

Edited by Dag Aarsland, Jeffrey Cummings, Daniel Weintraub and K. Ray Chaudhuri

Index

[More information](#)

## Index

- mild cognitive impairment (MCI) (cont.)  
 dementia prediction, 169  
 diagnostic criteria, 55, 163, 166–7, 173  
 functional impact, 168  
 neuroimaging correlates, 81  
 neuropathology, 170  
 patient/caregiver complaint, 168  
 prevalence, 163–5  
 progression, 168–9, 212  
 subtypes, 166  
 treatment, 172
- Mini-Mental Parkinson (MMP), 57
- Mini-Mental State Examination (MMSE), 56
- Minnesota Impulsive Disorders Interview (MIDI), 145
- minocycline, 11
- mitochondrial dysfunction, 2
- modafinil, 204
- monoamine oxidase (MAO), 27  
 genetic polymorphism, 28–9
- Montgomery-Åsberg Depression Rating Scale (MADRS), 66, 109
- Montreal Cognitive Assessment (MoCA), 56–7
- mood fluctuations, 277
- motivated behavior, dopaminergic treatment impacts, 217–18
- motivational deficits. *See* apathy
- motor fluctuations, 7, 275
- motor symptoms, 4–5
- Movement Disorder Society Unified Parkinson's Disease Rating Scale (MDS-UPDRS), 4–5, 124, 145
- movement disorders (MDs), 98
- multiple sleep latency test (MSLT), 202
- multiple systems atrophy (MSA), 261–3  
 cognitive features, 261–3  
 comparative studies, 268–72  
 attention, 270  
 executive function, 270  
 general cognition, 268–70  
 memory, 271  
 verbal fluency, 270  
 visuospatial skills, 270–1  
 neuropsychiatric/behavioral features, 263
- neurofibrillary tangles, 99–100
- neurofilaments, 102–3
- neuroimaging studies, 46, 73,  
*see also* functional imaging;  
*specific imaging techniques*
- correlates of cognitive and behavioral abnormalities, 76–84  
 anxiety, 79  
 apathy, 77–8, 135–6  
 cognitive impairment, 79–81, 170–1  
 dementia, 81–3  
 depression, 78–9, 111  
 impulse control disorders, 77, 143–4  
 psychosis, 78–9  
 sleep disturbance, 76–7  
 visual hallucinations, 80  
 white matter changes, 83–4
- image analysis, 75–6  
 automated/semi-automated methods, 75–6  
 qualitative visual assessments, 75
- image assessment  
 region of interest (ROI) methods, 75
- Parkinson's disease dementia (PDD), 73
- neuroleptics  
 dementia management, 187  
 hypersensitivity, 46, 155
- neuroprotective agents, 10
- Neuropsychiatric Inventory, 124
- neurotransmitter deficiencies, 43–4
- neurotrophic factors, 11
- nocturia, 198–9  
 management, 204
- nocturnal akinesia, 195  
 management, 202
- non-motor fluctuations (NMFs), 275–6  
 attention, 44  
 cognitive fluctuations, 278  
 diagnosis, 278–9  
 epidemiology, 275–6  
 pathophysiology, 276–7  
 psychiatric fluctuations, 276–80  
 anxiety, 277  
 apathy, 277  
 clinical manifestations, 277–8  
 depression, 277  
 psychotic fluctuations, 277–8  
 treatment, 279–80  
 deep brain stimulation (DBS), 279–80  
 pharmacotherapy, 279  
 wearing-off, 275
- non-motor symptoms, 4–6,  
*see also specific symptoms*  
 genetic correlates, 25–6, 34–5  
 neuroanatomic pathways, 16  
 quality of life impact, 255
- nortriptyline, 113
- nucleus basalis of Meynert (nbM), 182
- obsessive-compulsive disorder (OCD), 123  
 deep brain stimulation effects, 235
- obstructive sleep apnea (OSA), 198
- ondansetron, 158
- on/off phenomenon, 275,  
*see also* motor fluctuations;  
 non-motor fluctuations
- orthostatic hypotension, 5  
 dementia with Lewy bodies (DLB), 45  
 management, 10  
 Parkinson's disease dementia (PDD), 45
- oxidative stress, 2
- pain, 4
- PANDA (Parkinson Neuropsychometric Dementia Assessment), 58–9
- panic disorder, 67–8, 121, 123  
 panic attacks, 123
- parasomnias, 195–7, *see also* sleep disorders; *specific disorders*
- parkin* gene, 2–3
- Parkinson's disease (PD), 211  
 clinical course, 3–6  
 diagnostic phase, 4–5  
 prodromal phase, 3–4  
 progression, 6  
 clinical features, 4  
 differential diagnosis, 6  
 epidemiology, 1  
 etiology, 1–2  
 genetic basis, 2–3, 25,  
*see also* genetics  
 autosomal dominant forms, 3  
 autosomal recessive form, 3  
 idiopathic PD, 6  
 management. *See also specific treatments*  
 behavioral effects of symptomatic treatments, 286  
 disease-modifying treatments, 250–1, 285–6  
 future perspectives, 10–11  
 non-motor complications, 10  
 non-pharmacologic, 6–7  
 pharmacologic, 7–9  
 surgical, 9–10  
 motor symptoms, 4–5  
 neuropathology, 3  
 non-motor symptoms, 4–6,  
*see also specific symptoms*  
 genetic correlates, 25–6  
 neuroanatomic pathways, 16  
 quality of life impact, 255



Cambridge University Press

978-1-107-03922-3 - Neuropsychiatric and Cognitive Changes in Parkinson's Disease and Related Movement Disorders: Diagnosis and Management

Edited by Dag Aarsland, Jeffrey Cummings, Daniel Weintraub and K. Ray Chaudhuri

Index

[More information](#)

## Index

- pathogenesis, 2  
staging, 15–16
- Parkinson's disease dementia (PDD),  
17, 41, 81, *see also* dementia;  
dementia with Lewy bodies (DLB)
- biochemical correlates, 182–3
- biomarkers, 99–100
- boundaries with dementia with  
Lewy bodies (DLB), 40, 47–8
- clinical criteria, 40–2
- clinical symptoms, 44–6
- neurochemistry, 43–4
- neuropathology, 42–3
- definition, 42
- development, 54
- diagnosis, 46–7, 183–5
- cognitive tests, 46–7
- diagnostic criteria, 184–5
- functional imaging, 46–7, 90, 92
- structural imaging, 46, 81–3
- transcranial sonography, 47
- epidemiology, 177
- genetics, 178–9
- heredity, 46
- management, 47, 185–8
- cholinesterase inhibitors, 185–7
- memantine, 187
- neuroleptics, 187
- neuroimaging correlates, 73
- neuropathological correlates,  
181–2
- risk factors, 177–8
- symptoms, 44–6, 179–81, 184
- autonomic dysfunction, 45, 181
- behavioral features, 180–1
- cognitive features, 179–85
- cognitive impairment, 45
- dysphagia, 46
- fluctuations in attention and  
wakefulness, 44
- hallucinations, 75, 154–5
- motor features, 181
- neuroleptics
- hypersensitivity, 46
- parkinsonism, 44
- sleep disturbance, 45, 181
- Parkinson's disease psychosis (PDP),  
246, *see also* psychosis
- clinical trials, 244
- candidate targets, 245–6
- cohort design, 248
- core issues, 251
- data analysis, 248
- design considerations, 246–8
- disease modifying agents  
(DMAs), 250–1
- dosage issues, 248
- outcome measures, 248–50
- overview, 244–5
- PD psychosis inclusion criteria,  
246–7
- placebo effect, 248
- trial duration, 246
- Parkinson's disease sleep scale (PDSS),  
199–202
- parkinsonism
- dementia with Lewy bodies (DLB),  
44
- Parkinson's disease dementia  
(PDD), 44
- Parkinson-Plus. *See* atypical  
parkinsonian disorders
- paroxetine, 113
- PD-CRS (Parkinson's disease-  
cognitive rating scale), 59
- PDD. *See* Parkinson's disease  
dementia (PDD)
- PDD Short Screen, 57
- periodic limb movements (PLM), 197
- phobias, 123, *see also specific types of  
phobia*
- pimavanserin, 158, 287
- placebo effect, 248, 288–9
- polysomnography (PSG), 196, 202
- pontine nucleus (PPN), 11
- positron emission tomography (PET),  
89, *see also* functional  
imaging
- tracers, 91
- post-traumatic stress disorder (PTSD),  
123
- postural instability, 4
- postural instability gait disorder  
(PIGD), 44, 178, 181
- pramipexole, 219
- prazosin, 288
- prodromal phase, 3–4
- progressive supranuclear palsy (PSP),  
263–6
- cognitive features, 264–5
- comparative studies, 268–72
- attention, 270
- executive function, 270
- general cognition, 268–70
- memory, 271
- verbal fluency, 270
- visuospatial skills, 270–1
- neuropsychiatric/behavioral  
features, 265–6
- Richardson's syndrome (RS),  
264
- pseudobulbar affect (PBA), 288
- psychosis, 19–20, 153,  
*see also* Parkinson's disease  
psychosis
- associated conditions, 154
- clinical features, 153–5
- clinical trials. *See* Parkinson's  
disease psychosis
- complications, 159
- deep brain stimulation effects, 239
- epidemiology, 153
- genetic basis, 32–3
- neuroimaging correlates, 78–9
- quality of life impact, 257
- rating scales, 155
- risk factors, 155–7
- symptom fluctuations, 277–8
- treatment, 157–9, 218–19
- emerging antipsychotic agents,  
286–7
- punding, 146, 220
- assessment, 146
- correlates, 146
- deep brain stimulation effects, 238
- etiology, 146
- management, 146–7
- prevalence, 146
- quality of life. *See* health-related  
quality of life (HRQoL)
- Questionnaire for Impulsive-  
Compulsive Disorders in  
Parkinson's Disease (QUIP),  
145
- quetiapine, 157–8, 219
- clinical trials, 245
- rapid eye movement (REM) sleep  
disorder (RBD), 20–1, 76–7,  
181, 195–204
- as risk factor for dementia, 178
- clinical features, 195–6
- diagnostic criteria, 195–6
- differential diagnosis, 196–7
- management, 204
- screening questionnaire (RBDSQ),  
202
- rasagiline, 9, 250
- repetitive transcranial magnetic  
stimulation (rTMS), 114,  
219
- rest tremor, 4
- restless legs syndrome (RLS), 197
- management, 204
- Rey–Osterrieth Complex Figure  
Test, 56
- rigidity, 4
- riluzole, 10
- rivastigmine, 31, 47, 158, 186
- Scales for Outcomes in Parkinson's  
Disease (SCOPA)
- cognition (SCOPA-COG), 58–9
- sleep scale, 199–200
- schizophrenia, 286

Index

- screening
  - cognitive, 185
  - psychiatric, 124
- selective serotonin reuptake inhibitors (SSRI), 112
- selegiline, 9, 113
  - sleep disorders and, 199
- Self-Rating Depression Scale (SDS), 109
- sensory symptoms, 4
- serotonin
  - depression etiology, 33
  - functional imaging, 91
  - psychosis relationship, 157
- serotonin syndrome, 9
- shopping, compulsive, 77,
  - see also* impulse control disorders (ICD)
- deep brain stimulation (DBS) effect, 237
- sialorrhea, 10
- single photon emission tomography (SPECT), 89,
  - see also* functional imaging
- sleep disordered breathing (SDB), 198
- sleep disorders, 20–1, 45, 181, 192,
  - see also specific disorders*
  - as risk factor for dementia, 178
  - as risk factor for psychosis, 156
  - atypical parkinsonian disorders, comparisons, 271
- drug induced, 199
- epidemiology, 192–3
- future directions, 205
- investigations, 199–202
- management, 188, 202–3
  - deep brain stimulation (DBS), 205
  - developments, 288
  - sleep benefit, 202
  - sleep hygiene, 202
- multiple systems atrophy patients, 263
- neuroimaging correlates, 76–7
- neuropsychiatric comorbidities, 199–202, 204–5
- parasomnias, 195–7
- pathophysiology, 193–5
- progressive supranuclear palsy patients, 266
- types of, 193–4
- smoking, 178
- SNCA. *See* alpha-synuclein (SNCA) gene
- social adjustment, deep brain stimulation effects, 238
- social phobia, 68–9, 122–3
- specific phobia, 68
- Statistical Parametric Mapping (SPM) program, 75
- structural MRI. *See* magnetic resonance imaging (MRI)
- substantia nigra (SN), 14
  - hyperechogenicity, 75
- subthalamic neurostimulation.
  - See* deep brain stimulation (DBS)
- sudden onset sleep (SoS), 197–8
  - driving and, 198
- suicidal behavior, deep brain stimulation effects, 235, 238–9
- synuclein. *See* alpha-synuclein
- tau protein, 29, 97
  - as biomarker, 99–101
- TCH346, 10
- tolcapone, 8
- transcranial ultrasonography (TCS), 74
- Tretiakoff, Konstantin, 14
- trihexyphenidyl, 9
- ubiquitin, 2
- ubiquitin proteasome system (UPS), 2
- ultrasonography, 75
- Unified Parkinson's Disease Rating Scale (UPDRS), 4
- urinary dysfunction, 6, 10
- venlafaxine, 113
- ventral striatum, 19, 142, 214–15
- verbal fluency, 270
- visual hallucinations, 19–20, 153–4, 218, *see also* hallucinations dementia with Lewy bodies (DLB), 75
- fluctuations, 277–8
- neuroimaging correlates, 78–80
- Parkinson's disease dementia (PDD), 75
- prevalence, 153
- visuospatial skills
  - atypical parkinsonian disorders, comparisons, 270–1
  - impairment, 180
- walkabout, 146
- wearing-off, 275, 278
- white matter pathology, 46, 83–4
  - hyperintensities (WMH), 75, 83–4, 178
  - impact on cognition, 84
- WOQ-9 questionnaire, 278–9
- Zung Self-Rating Depression Scale (SDS), 109